Product Description
BOL-DP-O-05 is being developed by Breath of Life International Pharma as an add-on treatment for patients with type-1 diabetes. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04102202?term=BOL-DP-O-05&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Breath of Life International Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 1 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04102202 |
BOL-P-023 | P2 |
Withdrawn |
Type 1 Diabetes |
2021-03-22 |
50% |
2021-03-25 |
Recent News Events
Date |
Type |
Title |
|---|